Navigation Links
Saladax Biomedical, Inc. Enters Agreement with Kaan Medikal for Distribution of My5-FU in Turkey
Date:8/8/2011

BETHLEHEM, Pa., Aug. 8, 2011 /PRNewswire/ -- Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today that Kaan Medikal will serve as the exclusive distributor of Saladax's My5-FU diagnostic test throughout the Turkish market.

My5-FU measures levels of 5-flourouracil (5-FU), a widely used chemotherapy drug used in conjunction with other drugs in first-line therapy for colorectal cancer and other solid tumors.  The assay technology enables oncologists to determine the optimal dose of 5-FU for each individual patient, thereby increasing the effectiveness of the drug and lessening the risk of severe toxicity and side effects.  My5-FU is the first of Saladax's innovative dose management tests commercially available.

"Kaan Medikal is an ideal partner for Saladax as we continue to expand the distribution and marketing of My5-FU in the European Union and other significant markets," said Adrienne Choma, Esq., vice president, marketing and sales of Saladax.  "Interest in Turkey for My5-FU is strong, and we expect that Kaan Medikal's market leadership in diagnostic testing and excellent reputation for quality will enable significant opportunities for growth, which will translate into improved care for patients undergoing chemotherapy treatment for colorectal and other solid tumor cancers."

Fatih Ordu, general manager of Kaan Medikal, stated, "We are delighted to be working with Saladax to market My5-FU in Turkey.  We're confident that Saladax's innovative diagnostic test will allow physicians in our country to better monitor and provide more accurate treatment to their patients."

About Saladax Biomedical, Inc.

Saladax Biomedical develops and commercializes novel diagnostic assays to achieve the promise of personalized medicine through dose management and companion diagnostic products for existing and new therapeutics.  The Company's dose management technology enables physicians to optimize drug dosing to meet individual patient needs, leading to improved response and quality of life.  The Company's 15 MyCare™ dose management assays are comprised of proprietary, automated and cost-effective in vitro diagnostic tests, with a principal focus in oncology.  The first MyCare assay available is for one of the most common anticancer drugs, 5-fluorouracil (5-FU).  This assay is sold by Saladax in Europe as a CE-marked product and will be distributed in Japan by FALCO biosystems.  In the United States, Myriad Genetics provides testing for 5-FU through a license from Saladax.  Saladax also works with pharmaceutical companies to develop companion diagnostics to provide important clinical information to assist in developing and administering new and existing compounds.  For more information, visit www.saladax.com, or follow us on Twitter at https://twitter.com/Saladax.

Saladax Biomedical, Inc.
Adrienne Choma, Esq.
VP Marketing & Sales
achoma@saladax.com

Media Contact:
Tiberend Strategic Advisors, Inc.
212-827-0020
Andrew Mielach
amielach@tiberend.com
or
Jason Rando
jrando@tiberend.com


'/>"/>
SOURCE Saladax Biomedical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Saladax Biomedical, Inc. Completes $9 Million Debt Financing With GE Capital
2. Saladax Biomedical, Inc. Announces Pacific Rim Commercialization Team in Australia and China
3. Saladax Biomedicals 5-FU Personalized Chemotherapy Management (PCM(R)) Assay CE Marked for Distribution in the EU
4. Dainippon Sumitomo Pharma Co., Ltd. and Boston Biomedical, Inc. Enter Strategic Partnership on Anti-Cancer Drugs Targeting Cancer Stem Cells
5. BINDER BIOMEDICAL, INC. Announces Official Launch of the NEWTON™ Intervertebral Body Fusion Spinal Spacer System
6. Binder Biomedical, Inc. Announces the Release of the X-GRAFT(TM) Interspinous Device, as Part of Their QUANTUM(TM) Line of Spinal Allograft Devices, Manufactured at the University of Miami Tissue Bank
7. I-Flow Corporation Enters into Exclusive Government Distribution Agreement With Buffalo Supply, Inc.
8. Scottish Executive Awards Varian Medical Systems Major Contract to Supply Advanced Radiotherapy Equipment to Scotlands Five Cancer Centers
9. Watson Enters into Agreement to Acquire Products Related to Perrigos Acquisition of Paddock Laboratories
10. Newport Audiology Centers to Turn Up the Volume In Nashville
11. Double Eagle Holdings Enters Into Supply Agreement with Platform Delivery Technologies Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2017)... Provista , a proven leader in the supply chain industry ... Jim Cunniff as the company,s new president and CEO. ... Provista, including most recently serving as the president and CEO ... He assumed his new role with Provista on May 1, ... says Jody Hatcher , president, Sourcing and Collaboration Services ...
(Date:5/6/2017)... 2017  Hill-Rom Holdings, Inc. (NYSE: HRC), has begun ... feet to its Welch Allyn campus. ... bring more than 100 new jobs to ... maintained a significant presence for more than 100 years. ... a large portion of which will be R&D and ...
(Date:5/4/2017)... May 4, 2017  A recent study published ... Ultraviolet-C light as a means of disinfection ... to reduce bioburden on anesthesia workstations. In the ... high-touch, complex medical equipment surfaces contaminated with three ... "This study further validates the body of ...
Breaking Medicine Technology:
(Date:5/26/2017)... YORK, NY (PRWEB) , ... May 26, 2017 ... ... Board (SAB) met this week to review more than eighty-nine grant submissions ... experienced and emerging young scientists in the Parkinson’s field.     , The American Parkinson ...
(Date:5/26/2017)... ... May 26, 2017 , ... A new analysis of ... the healthiest seniors are located in the Midwest. With the average cost of healthcare ... people are concerned with both the quality and affordability of where they live. An ...
(Date:5/26/2017)... ... 26, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... on the Peace Agreements being discussed by President Donald Trump and the rest of ... try to speed up peace talks in the continuous battle between Israel and Palestine. ...
(Date:5/26/2017)... ... ... FLINTHILLS FAMILY-Our Journey to the Cross”: the personal journey of Bob Massey and his faith ... published authors, Bob and Margaret Massey. Bob Massey is small in stature but big ... tough." His love for others is apparent in all of his life decisions. ...
(Date:5/24/2017)... N.J. (PRWEB) , ... May 24, 2017 , ... ... Clara Maass Medical Center CEO Mary Ellen, hospital employees, and town officials to ... Belleville. , The facility was developed by Rendina as part of its ongoing ...
Breaking Medicine News(10 mins):